Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results